This study focuses on treating agitated behavior in people with dementia who have not responded well to standard treatments. The research will test three different medications: quetiapine, olanzapine, and lorazepam. These medications belong to a group of drugs called psychotropic drugs, which affect brain function and mental state. The purpose is to determine how well these medications work in controlling agitation symptoms in dementia patients.
During the study, participants will receive either one of the active medications or a placebo. The medications will be given in capsule form and taken by mouth. The treatment period will last for 6 weeks, during which the maximum daily doses will be 50mg for quetiapine, 10mg for olanzapine, or 2mg for lorazepam. To ensure that neither the patients nor the healthcare providers know which treatment is being given, all medications will be placed in identical capsules.
The study will monitor changes in agitated behavior over time using various assessment tools. Healthcare providers will track any side effects that may occur during the treatment period. This research specifically targets nursing home residents who have dementia with agitated behavior and whose doctors have determined they need medication to manage their symptoms.
The Netherlands 
